"TG Therapeutics has reached an agreement with the FDA regarding a Special Protocol Assessment for a phase III clinical trial exploring ublituximab (TG-1101, a chimeric recombinant glycoengineered monoclonal antibody directed against CD20) in combination with ibrutinib (Imbruvica) for the treatment of patients with chronic lymphocytic leukemia (CLL), the company announced last week."
"The randomized controlled trial is planned to enroll approximately 330 patients, who will receive ublituximab plus ibrutinib or ibrutinib alone. "
Watch out for more combination therapies with ibrutinib and Idelalisib.
Photo: Kookaburras in an old gum tree. The one on the left is about to enjoy a skink for lunch. The skink has dropped its tail as a diversionary tactic and which it can regrow. The tail wriggles and twists to attract the predator, but this time that ploy didn't work .